Longer Follow-Up Data Show Role of Osimertinib in NSCLC Treatment

The long-term results from an analysis of two phase II studies confirmed the role of osimertinib in the treatment of T790M mutation –positive advanced non–small-cell lung cancer.

Source: CancerNetwork - December 11, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news